Jci_page_head_homepage_01 Jci_page_head_homepage_02
Daniela Cota, Giovanni Marsicano, Matthias Tschöp, Yvonne Grübler, Cornelia Flachskamm, Mirjam Schubert, Dorothee Auer, Alexander Yassouridis, Christa Thöne-Reineke, Sylvia Ortmann, Federica Tomassoni, Cristina Cervino, Enzo Nisoli, Astrid C.E. Linthorst, Renato Pasquali, Beat Lutz, Günter K. Stalla, Uberto Pagotto
Published in Volume 112, Issue 3
J Clin Invest. 2003; 112(3):423–431 doi:10.1172/JCI17725
Abstract | Full text | PDF
Options: View larger image (or click on image)
Jci0317725
Figure 5

Functional CB1 is expressed in adipocytes. (a) RT-PCR for CB1 performed on CB1+/+ and CB1–/– epididymal fat pads. Ma, marker; lane 1, CB1+/+; lane 2, CB1–/–; lane 3, negative control for CB1+/+; lane 4, negative control for CB1–/–; lane 5, hippocampus; lane 6, water. (b) RT-PCR for CB1 performed on primary adipocyte cell cultures from C57BL/6N mice. Ma, marker; lane 1, C57BL/6N adipocytes; lane 2, negative control; lane 3, hippocampus; lane 4, water. (c) Effects of different doses of the CB1 agonist WIN-55,212 (WIN) and CB1 antagonist SR 141716A (SR) on heparin-releasable LPL activity (expressed as percentage of vehicle control) in primary adipocyte cells from C57BL/6N mice. *P < 0.05 compared with vehicle control. P < 0.05 compared with 10–6 M WIN.